1. Remdesivir for the treatment of COVID-19—final report.;Beigel;N Engl J Med,2020
2. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19.;Ohl;JAMA Netw Open,2021
3. U.S. Food and Drug Administration. FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness. Accessed May 24, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness
4. VA Pharmacy Benefits Management Services. Remdesivir emergency use authorization (EUA) requirements: May 2020. Accessed May 24, 2021. https://www.va.gov/covidtraining/docs/20200618_Dynamic_Drugs_in_the_Battle_of_COVID_19/Remdesivir_Emergency_Use_Authorization_Requirements.pdf
5. US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of Veklury (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. Accessed May 24, 2021. https://www.fda.gov/media/137566/download